TMCI
Treace Medical Concepts, Inc.2.7000
-0.0700-2.53%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Softness persists; strong new product adoption.
Q&A affirmed persistent foot-and-ankle softness into 2026, with deferred elective cases, but spotlighted share gains from new bunion systems—25% of 3,300 surgeons adopted them in two quarters, led by SpeedMTP fusions and Nanoplasty for MIS newbies. Guidance toggles on macro uncertainty (low end) versus product uptake like mid-year SuperBite screws and Speed XM plates (high end). Analysts probed sales dilution; management countered it's customer-driven, keeping bunion focus. Cash burn halves via OpEx leverage, trimmed med ed and DTC. New products clicked fast. Confident tone on execution; investors watch case acceleration, wallet share depth.
Key Stats
Market Cap
172.04MP/E (TTM)
-Basic EPS (TTM)
-0.80Dividend Yield
0%Recent Filings
8-K
Q4 revenue dips, FY up 2%
Treace Medical Concepts posted full-year 2025 revenue of $212.7 million, up 2% yet with Q4 down 9% to $62.5 million from lower-priced bunion kit sales. Net loss widened to $59.0 million, but adjusted EBITDA loss shrank 64% to $(3.9) million while cash burn dropped 46% to $27.3 million. Cash stands at $48.4 million plus $115 million credit facility. 2026 guides revenue to $200-$212 million, EBITDA loss $4-$6 million. Product mix headwinds persist.
10-K
FY2025 results
Treace Medical Concepts posted FY2025 revenue of $212.7M, up 1.6% y/y, with Q4 contributing meaningfully to the modest annual gain amid Lapiplasty sales softening from surgeon shifts to minimally invasive osteotomies and macroeconomic pressures on elective procedures. While bunion kit volumes rose, lower ASPs from new Nanoplasty/Percuplasty/SpeedMTP systems and $13M stocking distributor sales (mostly initial Q1-Q3 inventory builds) crimped margins to 79.8% from 80.4%. Sales/marketing expenses fell 4.6% on DTC cuts and sales force optimization, yet G&A surged 12.6% on litigation costs, yielding a $59.0M net loss versus $55.7M prior year. Q4 momentum built via new product adoption, but $60M SLR term debt refinanced MidCap obligations. Q4 accelerated. Litigation from IP rivals threatens quarterly cash flow.
8-K
Q4 revenue dips 9%
Treace Medical Concepts released preliminary Q4 2025 revenue of $62.1M-$62.5M, down 9% from 2024 amid headwinds, yet full-year hit $212.3M-$212.7M, up 2% and matching guidance. Active surgeons climbed 6% to 3,337, fueling mid-single-digit case growth via 3D bunion tech. No 2026 guidance yet. Momentum builds.
8-K
Secures $175M debt facility
Treace Medical Concepts secured a new 5-year $175M debt facility on December 17, 2025, drawing $60M term loan to refinance prior MidCap obligations, paying $2.3M prepay fees. The deal adds $65M term (revenue-tied) and $30M revolver (expandable to $50M), boosting liquidity to $165M. Secured by all assets. Board named John Bakewell lead independent director December 16.
10-Q
Q3 FY2025 results
Treace Medical Concepts posted Q3 revenue of $50.2M, up 11.4% y/y from $45.1M, with gross margin dipping to 79.1% from 80.1% on lower-margin stocking distributor sales. Operating loss held steady at $15.7M while sales/marketing costs rose modestly but YTD expenses fell 6.5% on optimized sales force; net loss widened slightly to $16.3M or $(0.26) per share on lower interest income and other non-operating costs, reconciled to 63.5M diluted shares. Cash burned $7.9M operationally YTD amid $11.1M capex, leaving $7.7M cash plus $49.7M short-term marketable securities against $54M debt (9%/7% rates, maturing 2027) with $23.2M revolver availability. New osteotomy kits drove kit volume yet faced Lapiplasty headwinds. Ongoing patent suits against Stryker and others intensify IP risks.
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
KIDS
OrthoPediatrics Corp.
17.91-0.08
MDNC
MEDINOTEC INC
5.00+0.00
OFIX
Orthofix Medical Inc.
15.55-0.16
PMI
Picard Medical, Inc.
2.30-0.13
TELA
TELA Bio, Inc.
1.18+0.05
TNON
Tenon Medical, Inc.
1.10+0.02
VERO
Venus Concept Inc.
2.26+0.59
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52